Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Q & A on Reverse Licensing

This article was originally published in Start Up

Executive Summary

An increasing amount of funding appears to be going to start-ups that in-license compounds from pharma companies in agreements known as reverse licensings. Some of the key points in structuring such a deal are: 1) defining the "licensed compound"; ensuring access to data and people; freedom to develop the compound in an unencumbered manner; buyback rights ;constructing sensible economics; and controlling the intellectual property.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts